Chen Ling-Yun, Song Yong-Ping
Department of Hematology, Cancer Hospital Affiliated to Zhengzhou University，Zhengzhou 450008，Henan Province，China.
Department of Hematology, Cancer Hospital Affiliated to Zhengzhou University，Zhengzhou 450008，Henan Province，China. E-mail：
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2020 Aug;28(4):1419-1423. doi: 10.19746/j.cnki.issn.1009-2137.2020.04.058.
Venetoclax is a selective inhibitor of the anti-apoptotic protein B-cell lymphoma 2（BCL-2）and has great potential in treating a variety of hematological tumors. In recent years, domestic and foreign scholars have tried to use venetoclax singal or in combination with some drugs to treat the patients with hematological tumors, including elderly acute myeloid leukemia（AML）patients un suitable for intensive chemotherapy, relapsed or refractory chronic lymphocytic leukemia（CLL）, Non-Hodgkin's lymphoma（NHL）and multiple myeloma（MM）patients, these studies have achieved good results．At the same time，some scholars found that the secondary drug-resistance occurred in some patients who continuous treated with Venetoclax, and explored the Venetoclax-resistant mechanism. In this review, the research advance of Venetoclax in hematological tumors and the mechanisms of drug resistance are summarized and discussed briefly.
维奈托克是抗凋亡蛋白B细胞淋巴瘤-2（BCL-2）的选择性抑制剂，在治疗多种血液肿瘤方面具有巨大潜力。近年来，国内外学者尝试使用维奈托克单药或与某些药物联合治疗血液肿瘤患者，包括不适合强化化疗的老年急性髓系白血病（AML）患者、复发或难治性慢性淋巴细胞白血病（CLL）、非霍奇金淋巴瘤（NHL）和多发性骨髓瘤（MM）患者，这些研究均取得了良好效果。同时，一些学者发现部分持续接受维奈托克治疗的患者出现了继发性耐药，并对维奈托克耐药机制进行了探索。在本综述中，简要总结并讨论了维奈托克在血液肿瘤中的研究进展及耐药机制。
